TABLE 2.
Effects of HCD on cerebrovascular reactivity: effects of limited EX
| Variable | WT | WT HCD | WT HCD EX | TGF | TGF HCD | TGF HCD EX |
|---|---|---|---|---|---|---|
| ACh | ||||||
| EAmax | 54.8 ± 2.4 | 28.9 ± 3.7### | 55.9 ± 3.9 | 27.3 ± 3.0*** | 28.3 ± 3.4*** | 58.4 ± 2.5 |
| pD2 | 7.51 ± 0.24 | 7.60 ± 0.34 | 7.42 ± 0.35 | 6.97 ± 0.21 | 7.84 ± 0.36 | 7.35 ± 0.19 |
| CGRP | ||||||
| EAmax | 54.9 ± 2.5 | 54.4 ± 1.8 | 53.1 ± 5.0 | 21.8 ± 2.3*** | 33.8 ± 5.0** | 52.6 ± 3.2 |
| pD2 | 7.20 ± 0.16 | 7.13 ± 0.22 | 7.53 ± 0.27 | 7.45 ± 0.42 | 7.19 ± 0.29 | 7.36 ± 0.25 |
| GSK | ||||||
| EAmax | 55.9 ± 4.5 | 31.5 ± 4.5## | 48.1 ± 1.5 | 25.8 ± 2.4*** | 31.1 ± 3.8** | 50.9 ± 2.5 |
| pD2 | 7.18 ± 0.24 | 7.77 ± 0.30 | 7.49 ± 0.18 | 7.68 ± 0.32 | 7.88 ± 0.31 | 7.97 ± 0.16 |
| LEV | ||||||
| EAmax | 60.3 ± 1.09 | 56.2 ± 2.4 | 59.5 ± 5.6 | 24.1 ± 2.4*** | 31.0 ± 3.5*** | 57.9 ± 3.3 |
| pD2 | 6.18 ± 0.23 | 6.97 ± 0.21 | 7.65 ± 0.30 | 7.89 ± 0.32 | 6.87 ± 0.35 | 6.95 ± 0.28 |
Data are means ± sem and are expressed as the maximal agonist response (EAmax) and potency [pD2, −log (EC50)] for cohort 2. EAmax is the percentage maximal dilation to ACh, CGRP, and TRPV4 channel opener (GSK1016790A) and KATP channel opener Lev (n = 3–5/group). **P < 0.01, ***P < 0.001 (differences compared with TGF HCD EX); ##P < 0.01, ###P < 0.001 (differences compared with WT controls and WT HCD EX; differences between genotypes are not indicated due to significant interactions between treatment condition and genotype).